Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn
Mankind Pharma Ltd 路 Others (Uncategorized) 路 16 Oct 2026, 12:57 am
Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved an additional investment of up to EUR 45Mn into wholly owned subsidiary Mankind Pharma (Netherlands) B.V. on 15th Oct'26, raising its total investment limit to EUR 50Mn. The subsidiary will utilize EUR 48Mn in cash instalments to acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx). ACTx specializes in next-generation CAR-T cancer therapies, focusing on non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic expansion into global, innovation-led oncology biopharmaceuticals.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA 路 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference 路 06 Nov 2026
- Please find attached intimation regarding ESG Rating 路 05 Nov 2026
- Intimation of participation in the Investor Conference. 路 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 路 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL 路 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet 路 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 路 27 Oct 2026
